

Special Issue

Insights into Tumor Cell Metabolism and Epigenetics

Message from the Guest Editors


Tumor cell metabolism is a complex and dynamic field in cancer research. Research in tumor cell metabolism is rapidly evolving, and ongoing studies aim to unravel the complexity of metabolic reprogramming in different cancer types. The intersection of cancer metabolism and epigenetics alterations represents a fascinating area of research that sheds light on how metabolic alterations influence the epigenetic landscape in cancer cells and vice versa. The intricate interplay between cancer metabolism and epigenetics highlights the complexity of cancer biology. This Special Issue aims to unravel these connections, potentially identifying new therapeutic avenues and biomarkers for diagnosis, prognosis, and treatment response in cancer patients. In this Special Issue, we welcome high-quality original research and review articles focusing on (but not limited to) the following topics: crosstalk between metabolism and epigenetics; metabolic reprogramming and epigenetics; therapeutic strategies; and biomarkers for diagnosis, prognosis, and treatment response.

Guest Editors

Dr. Sara Granja
Dr. Vera Miranda-Gonçalves
Dr. Filipa Vieira

Deadline for manuscript submissions

closed (31 December 2025)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 8.1
Indexed in PubMed



mdpi.com/si/194441

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 8.1
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-
Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).